IMU Stock Overview ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
ImmunoGen, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for ImmunoGen Historical stock prices Current Share Price US$28.74 52 Week High US$29.00 52 Week Low US$3.36 Beta 1.17 1 Month Change 7.04% 3 Month Change 110.09% 1 Year Change 615.55% 3 Year Change 226.59% 5 Year Change 482.96% Change since IPO 1,149.57%
Recent News & Updates
ImmunoGen Files Form 15 Feb 23 ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.
Forecast breakeven date pushed back to 2024 Dec 31
ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH Dec 11
FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer Dec 05 See more updates
ImmunoGen Files Form 15 Feb 23 ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.
Forecast breakeven date pushed back to 2024 Dec 31
ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH Dec 11
FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer Dec 05 AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion. Dec 01
AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion. Nov 30
Insider recently sold €1.4m worth of stock Nov 09
Forecast breakeven date moved forward to 2023 Nov 03
Third quarter 2023 earnings released: EPS: US$0.11 (vs US$0.31 loss in 3Q 2022) Nov 03
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer Oct 28
New major risk - Share price stability Oct 23
Insider recently sold €1.2m worth of stock Sep 20 ImmunoGen, Inc. Announces Executive Changes
President recently sold €15m worth of stock Aug 06 Immunogen, Inc. Reaffirmes Revenue Guidance for 2023 Aug 02
Forecast breakeven date moved forward to 2024 Aug 01
ImmunoGen, Inc. Announces Executive Changes Aug 01
Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.24 loss in 2Q 2022) Jul 31
ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress Jun 09
ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE Jun 05
ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer May 04
Forecast to breakeven in 2025 May 01
First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.095 loss in 1Q 2022) Apr 30
No longer forecast to breakeven Mar 10
Forecast to breakeven in 2025 Mar 02
Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs Jan 05 ImmunoGen, Inc. Announces Executive Changes
ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH Dec 13
ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer Nov 22
NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm) Nov 19
ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer Nov 15
Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2021) Nov 05
ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022 Nov 05
ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer Nov 02
ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO Sep 12
ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm Sep 01
Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021) Jul 30
ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022 Jul 30
ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO May 27
Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review May 24
First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021) May 07 ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer Mar 30
No longer forecast to breakeven Feb 28
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26 ImmunoGen, Inc. Appoint Executives
Forecast to breakeven in 2024 Feb 11
ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs Feb 01
Forecast to breakeven in 2024 Jan 01
ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH Dec 13
Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020) Oct 31
Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020) Jul 31
ImmunoGen, Inc. Announces Mature Data from Forward II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin in Recurrent Ovarian Cancer, Regardless of Platinum Status May 21
First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.17 loss in 1Q 2020) May 11
ImmunoGen, Inc. Provides Revenue Guidance for the Year of 2021 May 11
Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019) Mar 03 Shareholder Returns IMU DE Biotechs DE Market 7D 6.8% 4.0% 0.7% 1Y 615.5% -10.2% 8.4%
See full shareholder returns
Return vs Market: IMU exceeded the German Market which returned -1.4% over the past year.
Price Volatility Is IMU's price volatile compared to industry and market? IMU volatility IMU Average Weekly Movement 25.0% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: IMU's share price has been volatile over the past 3 months.
Volatility Over Time: IMU's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate.
Show more ImmunoGen, Inc. Fundamentals Summary How do ImmunoGen's earnings and revenue compare to its market cap? IMU fundamental statistics Market cap €7.76b Earnings (TTM ) -€68.27m Revenue (TTM ) €267.08m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IMU income statement (TTM ) Revenue US$287.61m Cost of Revenue US$211.62m Gross Profit US$76.00m Other Expenses US$149.52m Earnings -US$73.52m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -0.27 Gross Margin 26.42% Net Profit Margin -25.56% Debt/Equity Ratio 12.8%
How did IMU perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/02/12 13:48 End of Day Share Price 2024/02/12 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ImmunoGen, Inc. is covered by 19 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ling Wang Brean Capital John Newman Canaccord Genuity Mara Goldstein Cantor Fitzgerald & Co.
Show 16 more analysts 
